Performance of a commercial, type-specific enzyme-linked immunosorbent assay for detection of herpes simplex virus type 2-specific antibodies in Ugandans.
Two hundred forty-eight human immunodeficiency virus (HIV)-positive and 496 HIV-negative subjects in Uganda were tested by HerpeSelect herpes simplex virus type 2 enzyme-linked immunosorbent assay (ELISA) and Western blotting to optimize the ELISA for use in this population. A higher index cutoff value was required for optimal sensitivity and specificity, and overall performance of the assay was not affected by HIV status.
Laeyendecker
Oliver
O
National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
Henson
Charla
C
Gray
Ronald H
RH
Nguyen
Ruby H-N
RH
Horne
Bobbi Jo
BJ
Wawer
Maria J
MJ
Serwadda
David
D
Kiwanuka
Noah
N
Morrow
Rhoda Ashley
RA
Hogrefe
Wayne
W
Quinn
Thomas C
TC
D000914:Antibodies, Viral / Q000097:blood*; D015153:Blotting, Western; D004797:Enzyme-Linked Immunosorbent Assay; D018023:HIV Seronegativity; D006679:HIV Seropositivity / Q000150:complications; D006558:Herpes Genitalis / Q000175:diagnosis*; D018258:Herpesvirus 2, Human / Q000276:immunology*; D006801:Humans; D011933:Reagent Kits, Diagnostic; D012680:Sensitivity and Specificity; D014454:Uganda
D000914:Antibodies, Viral; D011933:Reagent Kits, Diagnostic